Microbubble ​​​​​​​​Thera nostics
 (therapeutics+ diagnostics) consists in using microbubble oscillations for targeted therapeutic applications with ultrasound imaging for guidance and monitoring

The Microbubble Theranostics Laboratory develops targeted therapies based on microbubble oscillations, controlled by steering of an ultrasound beam and guided and monitored by ultrasound contrast imaging. Our interests broadly cover the fields of ultrasound contrast imaging, ultrasound targeted therapy, targeted drug delivery, microbubble cell interactions and cancer therapy. 

For example, we are developing targeted therapies against cancer. Despite the recent successful development of numerous and diversified cancer therapies, cancer treatments still trigger important systemic toxicities and are curative in only subsets of patients. Therefore, it is deemed essential to design novel strategies and approaches to override such limitations and improve the efficacy of our arsenal against cancer. Spatial targeting of anti-tumor therapies can maximize the specificity of such therapies while reducing their systemic side effects and consequently enhance the overall efficacy of treatments against cancer. 

Microbubbles are intravascular contrast agents traditionally used as blood tracers for ultrasound imaging. Interestingly, microbubbles oscillate in an US field and can therefore interact with surrounding cells. In addition to the documented ability of microbubbles to increase vascular and cellular permeability, I recently showed that microbubbles and ultrasound can increase perfusion in skeletal muscle microvasculature by activating purinergic and nitric oxide mediated vasodilation. My innovative results establish the feasibility of locally augmenting the entry of peripheral mediators within a specific body site. 

In my laboratory, we are proposing to develop highly innovative ultrasound based image guided targeted therapies against cancer by exploiting recently identified molecular pathways to enhance therapeutic efficacy, notably for radiotherapy and immunotherapy against cancer. 
The novel targeted therapies have tangible potential for clinical translation to patients since all the individual components of the proposed therapy are already present in the clinical setting. My laboratory, hosted within the multidisciplinary research teams and infrastructures at the Centre de recherche du centre hospitalier de l’Université de Montréal (CRCHUM) is uniquely positioned to allow the development and thorough evaluation of promising and innovative targeted therapeutic strategies.